Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2023 | Impact of neoadjuvant chemo on pathological staging and survival in sarcomatoid bladder cancer

Arya Mariam Roy, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses the impact of neoadjuvant chemotherapy in sarcomatoid bladder cancer. This research aimed to help form consensus on an understudied rare and aggressive form of bladder cancer. Due to rarity, Dr Roy used a retrospective database study to analyse this variant, dividing patients into two cohorts, one with and one without neoadjuvant chemotherapy. The neoadjuvant chemotherapy group had significantly more pathological downstaging with a significantly higher survival rate. Adjustments made for age/weight/sex variables did not influence this significance. The main conclusion from this research is that neoadjuvant chemotherapy is underutilised in sarcomatoid bladder cancer treatment. Despite this, Dr Roy notes the limitations of retrospective data studies and suggests more studies and treatment options are required to fully develop the consensus for sarcomatoid bladder cancer disease treatment and management. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.